Reports

Industry Research Reports

Human Recombinant LIF - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Human Recombinant LIF - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Medical Devices & Consumables

Published Date: 2025-03-10

Pages: 128 Pages

Report ld: 4618769

application for samples

Request Sample

Custom reports

Customized Report

  • Description selected
  • Table of Contents selected
  • Table of Figures selected
  • Related Reports selected
  • PDFPDF Downloadselected
  • Description selected
  • Table of Contents selected
  • Table of Figures selected
  • Related Reports selected
  • PDFPDF Downloadselected

Human Recombinant LIF Market Size(US$)

den_QYR1
cagr

CAGR 2025-2031

6.5%

marketSize

Market Size,2031

USD 565

Million

Market Snapshot

Market Size in 2025 (Value)
US$ 387 million
Market Forecast in 2031(Value)
US$ 565 million
CAGR
6.5%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Human Recombinant LIF was estimated to be worth US$ 366 million in 2024 and is forecast to a readjusted size of US$ 565 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.

Leukemia inhibitory factor (LIF) is a pleiotropic factor produced by multiple cell types, including T cells, myelomonocytic lineage, fibroblasts, liver, heart, and melanoma. LIF promotes the long-term maintenance of embryonic stem cells by inhibiting spontaneous differentiation.

North American market for Human Recombinant LIF was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Human Recombinant LIF was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Human Recombinant LIF was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global key companies of Human Recombinant LIF include STEMCELL, Merck, YEASEN, Dalian Meilun Biotech Co., Ltd., R&D Systems, Inc., Thermo Fisher Scientific Inc., Cell Guidance Systems LLC, Prospec-Tany Technogene Ltd., ACROBiosystems, Neuromics, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Human Recombinant LIF, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Recombinant LIF by region & country, by Type, and by Application.

The Human Recombinant LIF market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Recombinant LIF.

MARKET SEGMENTATION

By Company

  • STEMCELL
  • Merck
  • YEASEN
  • Dalian Meilun Biotech Co., Ltd.
  • R&D Systems, Inc.
  • Thermo Fisher Scientific Inc.
  • Cell Guidance Systems LLC
  • Prospec-Tany Technogene Ltd.
  • ACROBiosystems
  • Neuromics
  • BioLegend, Inc
  • InVitria
  • BPS Bioscience
  • ScienCell Research Laboratories, Inc

Consumption by Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Segment by Type

  • Purity < 97%
  • Purity ≥ 97%

Segment by Application

  • Laboratory
  • University
  • Others

biaoTi CHAPTER OUTLINE

marn_i1

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

marn_i1

Chapter 2: Detailed analysis of Human Recombinant LIF manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

marn_i1

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

marn_i1

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

marn_i1

Chapter 5: Sales, revenue of Human Recombinant LIF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

marn_i1

Chapter 6: Sales, revenue of Human Recombinant LIF in country level. It provides sigmate data by Type, and by Application for each country/region.

marn_i1

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

marn_i1

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

marn_i1

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region
Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

den_ic6
Product mix optimization based on local practices
Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

den_ic6
Competitor tactics in fragmented vs. consolidated markets
Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

den_ic6
Full Research Coverage
Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

den_ic6
19 Years Industry Expertise
19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

den_ic6
24/7 Fast Report Delivery
24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

den_ic6
Localized Strategic Analysis
Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

den_ic6
Market entry risks/opportunities by region
Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

den_ic6
Market entry risks/opportunities by region
Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

den_ic6
den_biaoTiZhungShi

TABLE OF CONTENTS

muLu

1 Market Overview

1.1 Human Recombinant LIF Product Introduction

1.2 Global Human Recombinant LIF Market Size Forecast

1.2.1 Global Human Recombinant LIF Sales Value (2020-2031)

1.2.2 Global Human Recombinant LIF Sales Volume (2020-2031)

1.2.3 Global Human Recombinant LIF Sales Price (2020-2031)

1.3 Human Recombinant LIF Market Trends & Drivers

1.3.1 Human Recombinant LIF Industry Trends

1.3.2 Human Recombinant LIF Market Drivers & Opportunity

1.3.3 Human Recombinant LIF Market Challenges

1.3.4 Human Recombinant LIF Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

muLu

2 Competitive Analysis by Company

2.1 Global Human Recombinant LIF Players Revenue Ranking (2024)

2.2 Global Human Recombinant LIF Revenue by Company (2020-2025)

2.3 Global Human Recombinant LIF Players Sales Volume Ranking (2024)

2.4 Global Human Recombinant LIF Sales Volume by Company Players (2020-2025)

2.5 Global Human Recombinant LIF Average Price by Company (2020-2025)

2.6 Key Manufacturers Human Recombinant LIF Manufacturing Base and Headquarters

2.7 Key Manufacturers Human Recombinant LIF Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Human Recombinant LIF

2.9 Human Recombinant LIF Market Competitive Analysis

2.9.1 Human Recombinant LIF Market Concentration Rate (2020-2025)

2.9.2 Global 5 and 10 Largest Manufacturers by Human Recombinant LIF Revenue in 2024

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Recombinant LIF as of 2024)

2.10 Mergers & Acquisitions, Expansion

muLu

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Purity < 97%

3.1.2 Purity ≥ 97%

3.2 Global Human Recombinant LIF Sales Value by Type

3.2.1 Global Human Recombinant LIF Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Human Recombinant LIF Sales Value, by Type (2020-2031)

3.2.3 Global Human Recombinant LIF Sales Value, by Type (%) (2020-2031)

3.3 Global Human Recombinant LIF Sales Volume by Type

3.3.1 Global Human Recombinant LIF Sales Volume by Type (2020 VS 2024 VS 2031)

3.3.2 Global Human Recombinant LIF Sales Volume, by Type (2020-2031)

3.3.3 Global Human Recombinant LIF Sales Volume, by Type (%) (2020-2031)

3.4 Global Human Recombinant LIF Average Price by Type (2020-2031)

muLu

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Laboratory

4.1.2 University

4.1.3 Others

4.2 Global Human Recombinant LIF Sales Value by Application

4.2.1 Global Human Recombinant LIF Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Human Recombinant LIF Sales Value, by Application (2020-2031)

4.2.3 Global Human Recombinant LIF Sales Value, by Application (%) (2020-2031)

4.3 Global Human Recombinant LIF Sales Volume by Application

4.3.1 Global Human Recombinant LIF Sales Volume by Application (2020 VS 2024 VS 2031)

4.3.2 Global Human Recombinant LIF Sales Volume, by Application (2020-2031)

4.3.3 Global Human Recombinant LIF Sales Volume, by Application (%) (2020-2031)

4.4 Global Human Recombinant LIF Average Price by Application (2020-2031)

muLu

5 Segmentation by Region

5.1 Global Human Recombinant LIF Sales Value by Region

5.1.1 Global Human Recombinant LIF Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Human Recombinant LIF Sales Value by Region (2020-2025)

5.1.3 Global Human Recombinant LIF Sales Value by Region (2026-2031)

5.1.4 Global Human Recombinant LIF Sales Value by Region (%), (2020-2031)

5.2 Global Human Recombinant LIF Sales Volume by Region

5.2.1 Global Human Recombinant LIF Sales Volume by Region: 2020 VS 2024 VS 2031

5.2.2 Global Human Recombinant LIF Sales Volume by Region (2020-2025)

5.2.3 Global Human Recombinant LIF Sales Volume by Region (2026-2031)

5.2.4 Global Human Recombinant LIF Sales Volume by Region (%), (2020-2031)

5.3 Global Human Recombinant LIF Average Price by Region (2020-2031)

5.4 North America

5.4.1 North America Human Recombinant LIF Sales Value, 2020-2031

5.4.2 North America Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031

5.5 Europe

5.5.1 Europe Human Recombinant LIF Sales Value, 2020-2031

5.5.2 Europe Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031

5.6 Asia Pacific

5.6.1 Asia Pacific Human Recombinant LIF Sales Value, 2020-2031

5.6.2 Asia Pacific Human Recombinant LIF Sales Value by Region (%), 2024 VS 2031

5.7 South America

5.7.1 South America Human Recombinant LIF Sales Value, 2020-2031

5.7.2 South America Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031

5.8 Middle East & Africa

5.8.1 Middle East & Africa Human Recombinant LIF Sales Value, 2020-2031

5.8.2 Middle East & Africa Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031

muLu

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Human Recombinant LIF Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Human Recombinant LIF Sales Value and Sales Volume

6.2.1 Key Countries/Regions Human Recombinant LIF Sales Value, 2020-2031

6.2.2 Key Countries/Regions Human Recombinant LIF Sales Volume, 2020-2031

6.3 United States

6.3.1 United States Human Recombinant LIF Sales Value, 2020-2031

6.3.2 United States Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Human Recombinant LIF Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Human Recombinant LIF Sales Value, 2020-2031

6.4.2 Europe Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Human Recombinant LIF Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Human Recombinant LIF Sales Value, 2020-2031

6.5.2 China Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031

6.5.3 China Human Recombinant LIF Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Human Recombinant LIF Sales Value, 2020-2031

6.6.2 Japan Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Human Recombinant LIF Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Human Recombinant LIF Sales Value, 2020-2031

6.7.2 South Korea Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Human Recombinant LIF Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Human Recombinant LIF Sales Value, 2020-2031

6.8.2 Southeast Asia Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Human Recombinant LIF Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Human Recombinant LIF Sales Value, 2020-2031

6.9.2 India Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031

6.9.3 India Human Recombinant LIF Sales Value by Application, 2024 VS 2031

muLu

7 Company Profiles

7.1 STEMCELL

7.1.1 STEMCELL Company Information

7.1.2 STEMCELL Introduction and Business Overview

7.1.3 STEMCELL Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.1.4 STEMCELL Human Recombinant LIF Product Offerings

7.1.5 STEMCELL Recent Development

7.2 Merck

7.2.1 Merck Company Information

7.2.2 Merck Introduction and Business Overview

7.2.3 Merck Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.2.4 Merck Human Recombinant LIF Product Offerings

7.2.5 Merck Recent Development

7.3 YEASEN

7.3.1 YEASEN Company Information

7.3.2 YEASEN Introduction and Business Overview

7.3.3 YEASEN Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.3.4 YEASEN Human Recombinant LIF Product Offerings

7.3.5 YEASEN Recent Development

7.4 Dalian Meilun Biotech Co., Ltd.

7.4.1 Dalian Meilun Biotech Co., Ltd. Company Information

7.4.2 Dalian Meilun Biotech Co., Ltd. Introduction and Business Overview

7.4.3 Dalian Meilun Biotech Co., Ltd. Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.4.4 Dalian Meilun Biotech Co., Ltd. Human Recombinant LIF Product Offerings

7.4.5 Dalian Meilun Biotech Co., Ltd. Recent Development

7.5 R&D Systems, Inc.

7.5.1 R&D Systems, Inc. Company Information

7.5.2 R&D Systems, Inc. Introduction and Business Overview

7.5.3 R&D Systems, Inc. Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.5.4 R&D Systems, Inc. Human Recombinant LIF Product Offerings

7.5.5 R&D Systems, Inc. Recent Development

7.6 Thermo Fisher Scientific Inc.

7.6.1 Thermo Fisher Scientific Inc. Company Information

7.6.2 Thermo Fisher Scientific Inc. Introduction and Business Overview

7.6.3 Thermo Fisher Scientific Inc. Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.6.4 Thermo Fisher Scientific Inc. Human Recombinant LIF Product Offerings

7.6.5 Thermo Fisher Scientific Inc. Recent Development

7.7 Cell Guidance Systems LLC

7.7.1 Cell Guidance Systems LLC Company Information

7.7.2 Cell Guidance Systems LLC Introduction and Business Overview

7.7.3 Cell Guidance Systems LLC Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.7.4 Cell Guidance Systems LLC Human Recombinant LIF Product Offerings

7.7.5 Cell Guidance Systems LLC Recent Development

7.8 Prospec-Tany Technogene Ltd.

7.8.1 Prospec-Tany Technogene Ltd. Company Information

7.8.2 Prospec-Tany Technogene Ltd. Introduction and Business Overview

7.8.3 Prospec-Tany Technogene Ltd. Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.8.4 Prospec-Tany Technogene Ltd. Human Recombinant LIF Product Offerings

7.8.5 Prospec-Tany Technogene Ltd. Recent Development

7.9 ACROBiosystems

7.9.1 ACROBiosystems Company Information

7.9.2 ACROBiosystems Introduction and Business Overview

7.9.3 ACROBiosystems Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.9.4 ACROBiosystems Human Recombinant LIF Product Offerings

7.9.5 ACROBiosystems Recent Development

7.10 Neuromics

7.10.1 Neuromics Company Information

7.10.2 Neuromics Introduction and Business Overview

7.10.3 Neuromics Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.10.4 Neuromics Human Recombinant LIF Product Offerings

7.10.5 Neuromics Recent Development

7.11 BioLegend, Inc

7.11.1 BioLegend, Inc Company Information

7.11.2 BioLegend, Inc Introduction and Business Overview

7.11.3 BioLegend, Inc Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.11.4 BioLegend, Inc Human Recombinant LIF Product Offerings

7.11.5 BioLegend, Inc Recent Development

7.12 InVitria

7.12.1 InVitria Company Information

7.12.2 InVitria Introduction and Business Overview

7.12.3 InVitria Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.12.4 InVitria Human Recombinant LIF Product Offerings

7.12.5 InVitria Recent Development

7.13 BPS Bioscience

7.13.1 BPS Bioscience Company Information

7.13.2 BPS Bioscience Introduction and Business Overview

7.13.3 BPS Bioscience Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.13.4 BPS Bioscience Human Recombinant LIF Product Offerings

7.13.5 BPS Bioscience Recent Development

7.14 ScienCell Research Laboratories, Inc

7.14.1 ScienCell Research Laboratories, Inc Company Information

7.14.2 ScienCell Research Laboratories, Inc Introduction and Business Overview

7.14.3 ScienCell Research Laboratories, Inc Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)

7.14.4 ScienCell Research Laboratories, Inc Human Recombinant LIF Product Offerings

7.14.5 ScienCell Research Laboratories, Inc Recent Development

muLu

8 Industry Chain Analysis

8.1 Human Recombinant LIF Industrial Chain

8.2 Human Recombinant LIF Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Human Recombinant LIF Sales Model

8.5.2 Sales Channel

8.5.3 Human Recombinant LIF Distributors

muLu

9 Research Findings and Conclusion

muLu

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

den_biaoTiZhungShi

TABLE OF FIGURES

muLu

List of Tables

Table 1. Human Recombinant LIF Market Trends
Table 2. Human Recombinant LIF Market Drivers & Opportunity
Table 3. Human Recombinant LIF Market Challenges
Table 4. Human Recombinant LIF Market Restraints
Table 5. Global Human Recombinant LIF Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Human Recombinant LIF Revenue Market Share by Company (2020-2025)
Table 7. Global Human Recombinant LIF Sales Volume by Company (2020-2025) & (K Units)
Table 8. Global Human Recombinant LIF Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Human Recombinant LIF Price by Company (2020-2025) & (US$/Unit)
Table 10. Key Manufacturers Human Recombinant LIF Manufacturing Base and Headquarters
Table 11. Key Manufacturers Human Recombinant LIF Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Human Recombinant LIF
Table 13. Global Human Recombinant LIF Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Recombinant LIF as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Human Recombinant LIF Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Human Recombinant LIF Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Human Recombinant LIF Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Human Recombinant LIF Sales Market Share in Value by Type (2020-2025)
Table 20. Global Human Recombinant LIF Sales Market Share in Value by Type (2026-2031)
Table 21. Global Human Recombinant LIF Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global Human Recombinant LIF Sales Volume by Type (2020-2025) & (K Units)
Table 23. Global Human Recombinant LIF Sales Volume by Type (2026-2031) & (K Units)
Table 24. Global Human Recombinant LIF Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Human Recombinant LIF Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Human Recombinant LIF Price by Type (2020-2025) & (US$/Unit)
Table 27. Global Human Recombinant LIF Price by Type (2026-2031) & (US$/Unit)
Table 28. Global Human Recombinant LIF Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Human Recombinant LIF Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global Human Recombinant LIF Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global Human Recombinant LIF Sales Market Share in Value by Application (2020-2025)
Table 32. Global Human Recombinant LIF Sales Market Share in Value by Application (2026-2031)
Table 33. Global Human Recombinant LIF Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
Table 34. Global Human Recombinant LIF Sales Volume by Application (2020-2025) & (K Units)
Table 35. Global Human Recombinant LIF Sales Volume by Application (2026-2031) & (K Units)
Table 36. Global Human Recombinant LIF Sales Market Share in Volume by Application (2020-2025)
Table 37. Global Human Recombinant LIF Sales Market Share in Volume by Application (2026-2031)
Table 38. Global Human Recombinant LIF Price by Application (2020-2025) & (US$/Unit)
Table 39. Global Human Recombinant LIF Price by Application (2026-2031) & (US$/Unit)
Table 40. Global Human Recombinant LIF Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Human Recombinant LIF Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Human Recombinant LIF Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Human Recombinant LIF Sales Value by Region (2020-2025) & (%)
Table 44. Global Human Recombinant LIF Sales Value by Region (2026-2031) & (%)
Table 45. Global Human Recombinant LIF Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
Table 46. Global Human Recombinant LIF Sales Volume by Region (2020-2025) & (K Units)
Table 47. Global Human Recombinant LIF Sales Volume by Region (2026-2031) & (K Units)
Table 48. Global Human Recombinant LIF Sales Volume by Region (2020-2025) & (%)
Table 49. Global Human Recombinant LIF Sales Volume by Region (2026-2031) & (%)
Table 50. Global Human Recombinant LIF Average Price by Region (2020-2025) & (US$/Unit)
Table 51. Global Human Recombinant LIF Average Price by Region (2026-2031) & (US$/Unit)
Table 52. Key Countries/Regions Human Recombinant LIF Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Human Recombinant LIF Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Human Recombinant LIF Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Human Recombinant LIF Sales Volume, (2020-2025) & (K Units)
Table 56. Key Countries/Regions Human Recombinant LIF Sales Volume, (2026-2031) & (K Units)
Table 57. STEMCELL Company Information
Table 58. STEMCELL Introduction and Business Overview
Table 59. STEMCELL Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 60. STEMCELL Human Recombinant LIF Product Offerings
Table 61. STEMCELL Recent Development
Table 62. Merck Company Information
Table 63. Merck Introduction and Business Overview
Table 64. Merck Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 65. Merck Human Recombinant LIF Product Offerings
Table 66. Merck Recent Development
Table 67. YEASEN Company Information
Table 68. YEASEN Introduction and Business Overview
Table 69. YEASEN Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 70. YEASEN Human Recombinant LIF Product Offerings
Table 71. YEASEN Recent Development
Table 72. Dalian Meilun Biotech Co., Ltd. Company Information
Table 73. Dalian Meilun Biotech Co., Ltd. Introduction and Business Overview
Table 74. Dalian Meilun Biotech Co., Ltd. Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Dalian Meilun Biotech Co., Ltd. Human Recombinant LIF Product Offerings
Table 76. Dalian Meilun Biotech Co., Ltd. Recent Development
Table 77. R&D Systems, Inc. Company Information
Table 78. R&D Systems, Inc. Introduction and Business Overview
Table 79. R&D Systems, Inc. Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. R&D Systems, Inc. Human Recombinant LIF Product Offerings
Table 81. R&D Systems, Inc. Recent Development
Table 82. Thermo Fisher Scientific Inc. Company Information
Table 83. Thermo Fisher Scientific Inc. Introduction and Business Overview
Table 84. Thermo Fisher Scientific Inc. Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Thermo Fisher Scientific Inc. Human Recombinant LIF Product Offerings
Table 86. Thermo Fisher Scientific Inc. Recent Development
Table 87. Cell Guidance Systems LLC Company Information
Table 88. Cell Guidance Systems LLC Introduction and Business Overview
Table 89. Cell Guidance Systems LLC Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Cell Guidance Systems LLC Human Recombinant LIF Product Offerings
Table 91. Cell Guidance Systems LLC Recent Development
Table 92. Prospec-Tany Technogene Ltd. Company Information
Table 93. Prospec-Tany Technogene Ltd. Introduction and Business Overview
Table 94. Prospec-Tany Technogene Ltd. Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. Prospec-Tany Technogene Ltd. Human Recombinant LIF Product Offerings
Table 96. Prospec-Tany Technogene Ltd. Recent Development
Table 97. ACROBiosystems Company Information
Table 98. ACROBiosystems Introduction and Business Overview
Table 99. ACROBiosystems Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. ACROBiosystems Human Recombinant LIF Product Offerings
Table 101. ACROBiosystems Recent Development
Table 102. Neuromics Company Information
Table 103. Neuromics Introduction and Business Overview
Table 104. Neuromics Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. Neuromics Human Recombinant LIF Product Offerings
Table 106. Neuromics Recent Development
Table 107. BioLegend, Inc Company Information
Table 108. BioLegend, Inc Introduction and Business Overview
Table 109. BioLegend, Inc Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. BioLegend, Inc Human Recombinant LIF Product Offerings
Table 111. BioLegend, Inc Recent Development
Table 112. InVitria Company Information
Table 113. InVitria Introduction and Business Overview
Table 114. InVitria Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. InVitria Human Recombinant LIF Product Offerings
Table 116. InVitria Recent Development
Table 117. BPS Bioscience Company Information
Table 118. BPS Bioscience Introduction and Business Overview
Table 119. BPS Bioscience Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120. BPS Bioscience Human Recombinant LIF Product Offerings
Table 121. BPS Bioscience Recent Development
Table 122. ScienCell Research Laboratories, Inc Company Information
Table 123. ScienCell Research Laboratories, Inc Introduction and Business Overview
Table 124. ScienCell Research Laboratories, Inc Human Recombinant LIF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 125. ScienCell Research Laboratories, Inc Human Recombinant LIF Product Offerings
Table 126. ScienCell Research Laboratories, Inc Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Human Recombinant LIF Downstream Customers
Table 130. Human Recombinant LIF Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
muLu

List of Figures

Figure 1. Human Recombinant LIF Product Picture
Figure 2. Global Human Recombinant LIF Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Human Recombinant LIF Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Human Recombinant LIF Sales Volume (2020-2031) & (K Units)
Figure 5. Global Human Recombinant LIF Sales Price (2020-2031) & (US$/Unit)
Figure 6. Human Recombinant LIF Report Years Considered
Figure 7. Global Human Recombinant LIF Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Human Recombinant LIF Players Sales Volume Ranking (2024) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Human Recombinant LIF Revenue in 2024
Figure 10. Human Recombinant LIF Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Purity < 97% Picture
Figure 12. Purity ≥ 97% Picture
Figure 13. Global Human Recombinant LIF Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 14. Global Human Recombinant LIF Sales Value Market Share by Type, 2024 & 2031
Figure 15. Global Human Recombinant LIF Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
Figure 16. Global Human Recombinant LIF Sales Volume Market Share by Type, 2024 & 2031
Figure 17. Global Human Recombinant LIF Price by Type (2020-2031) & (US$/Unit)
Figure 18. Product Picture of Laboratory
Figure 19. Product Picture of University
Figure 20. Product Picture of Others
Figure 21. Global Human Recombinant LIF Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 22. Global Human Recombinant LIF Sales Value Market Share by Application, 2024 & 2031
Figure 23. Global Human Recombinant LIF Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
Figure 24. Global Human Recombinant LIF Sales Volume Market Share by Application, 2024 & 2031
Figure 25. Global Human Recombinant LIF Price by Application (2020-2031) & (US$/Unit)
Figure 26. North America Human Recombinant LIF Sales Value (2020-2031) & (US$ Million)
Figure 27. North America Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031
Figure 28. Europe Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 29. Europe Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031
Figure 30. Asia Pacific Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 31. Asia Pacific Human Recombinant LIF Sales Value by Region (%), 2024 VS 2031
Figure 32. South America Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 33. South America Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031
Figure 34. Middle East & Africa Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 35. Middle East & Africa Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031
Figure 36. Key Countries/Regions Human Recombinant LIF Sales Value (%), (2020-2031)
Figure 37. Key Countries/Regions Human Recombinant LIF Sales Volume (%), (2020-2031)
Figure 38. United States Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 39. United States Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
Figure 40. United States Human Recombinant LIF Sales Value by Application (%), 2024 VS 2031
Figure 41. Europe Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 42. Europe Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
Figure 43. Europe Human Recombinant LIF Sales Value by Application (%), 2024 VS 2031
Figure 44. China Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 45. China Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
Figure 46. China Human Recombinant LIF Sales Value by Application (%), 2024 VS 2031
Figure 47. Japan Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 48. Japan Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
Figure 49. Japan Human Recombinant LIF Sales Value by Application (%), 2024 VS 2031
Figure 50. South Korea Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 51. South Korea Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
Figure 52. South Korea Human Recombinant LIF Sales Value by Application (%), 2024 VS 2031
Figure 53. Southeast Asia Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 54. Southeast Asia Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
Figure 55. Southeast Asia Human Recombinant LIF Sales Value by Application (%), 2024 VS 2031
Figure 56. India Human Recombinant LIF Sales Value, (2020-2031) & (US$ Million)
Figure 57. India Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
Figure 58. India Human Recombinant LIF Sales Value by Application (%), 2024 VS 2031
Figure 59. Human Recombinant LIF Industrial Chain
Figure 60. Human Recombinant LIF Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
den_biaoTiZhungShi

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global Human Recombinant LIF market size from 2025 to 2031?zhanKai
The annual compound growth rate of the global Human Recombinant LIF market is 6.5% 2025 to 2031.
Which companies rank high in the global Human Recombinant LIF market?shouQi
What was the global market size of Human Recombinant LIF in 2025?shouQi
Which region is expected to have the highest market share?shouQi
What was the global market size of Human Recombinant LIF in 2031?shouQi
den_biaoTiZhungShi

Related Reports

Human Recombinant LIF - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Medical Devices & Consumables

Published Date: 2025-03-10

Pages: 128 Pages

Report ld: 4618769

CHOOSE LICENSE TYPE
tip

USD 3950.00

tip

USD 5925.00

tip

USD 7900.00

Add to Cart

Add to Cart

Buy Now

Buy Now

HAVE A QUESTION?
SIMON LEE

English,Chinese

Offline

HITESH

English, Hindi

Offline

TANG XIN

Japanese,English

Offline

SUNG-BIN YOON

SUNG-BIN YOON

+82-2883 1278

Korean, English

Offline

YUJIE TIAN

Chinese, English

Offline

DAMON

Chinese, English

Offline

General Email:

REPORT COVERAGE

den_ic8

DESCRIPTION

zhankai
den_ic7

OVERVIEW

den_ic7

MARKET SEGMENTATION

den_ic7

CHAPTER OUTLINE

den_ic7

QYRESEARCH'S STRENGTHS

den_ic8

TABLE OF CONTENTS

den_ic8

TABLE OF FIGURES

den_ic8

RLEATED REPORTS

INTEREST IN THIS REPORT?

yangBenGet A Free Sample

baoJia Request For Quotation

OR

NEED A CUSTOMIZED REPORT?

DingZhiCustomized Report

biaoTi

WORLD WIDE OFFICE

application for samples

Request Sample

Custom reports

Pre-Order Enquiry

Add to Cart

Add to Cart

Buy Now

Buy Now